Patheon IncTSX: PTI

CEPH International Receives FDA Warning Letter

· Issued by Patheon Inc via CNW
TORONTO, Sept. 19 /CNW/ - Patheon Inc. (TSX: PTI) today announced that
CEPH International Corporation (CEPH) received late Friday afternoon
(Eastern Time) a Warning Letter from the San Juan, Puerto Rico District office
of the U.S. Food and Drug Administration, (FDA). CEPH, a subsidiary of MOVA
Pharmaceutical Corporation which was acquired by Patheon in December 2004,
operates a facility in Carolina, Puerto Rico. The Warning Letter claims that
variations in assay, fill-weight, content uniformity and related issues for an
oral powder for suspension product manufactured by CEPH indicate a failure by
CEPH to comply with current Good Manufacturing Practices (cGMP) of the U.S.
Federal Food, Drug and Cosmetic Act.
This action resulted from the FDA inspection of CEPH's manufacturing
facilities which was completed in April 2005. CEPH is required to respond to
the Warning Letter within 15 working days with details of the specific steps
CEPH has taken or will take to correct the situation.
In response to the FDA's concerns, CEPH has taken several actions,
including purchasing new equipment which is currently under validation.
Patheon is taking immediate action to address the concerns raised by the FDA
and a senior team of Patheon specialists will be working closely with CEPH
management and CEPH's client in this regard.
Patheon will issue a further news release if material developments occur
with respect to this matter.

Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug
development and manufacturing services to the international pharmaceutical
industry. With the addition of its wholly owned subsidiary MOVA Pharmaceutical
Corporation, acquired in December 2004, Patheon operates a network of
14 facilities in the United States, Canada and Europe, employing more than
5,900 people and serving a client base of 180 pharmaceutical and biotechnology
companies.
%SEDAR: 00001700E

Patheon Inc on 6ix

In the deck

Earlier from Patheon

Later from Patheon

All Patheon news releases